3rd Quarter - Report

ABBVIE, INC. for ABBVIE INC.

Firm
Client
Income
—
Expenses
$1,920,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans-Atlantic Trade and Investment Partnership; Trans-Pacific Partnership Agreement; Colombia OECD Accession; Renewed engagement possibilities with Argentina; Colombia Special 301 Out-of-Cycle Review; Saudi Arabia recent developments report to USTR;

LobbyistCovered position, as disclosed
DANIEL BACHNER —
MICHAEL D BOYD —
JOHN P. FORD —
STEPHEN SCANGO —
HEATHER STRAWN —

Contacted: Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); SENATE; Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); U.S. Trade Representative (USTR)

Copyright/Patent/Trademark CPT

H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015; S. 1878, Advancing Hope Act of 2015; S. 632, STRONG Patents Act of 2015; H.R. 9, Innovation Act; S. 2733, Venue Equity and Non-Uniformity Elimination Act of 2016; H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015; H.R. 5573 & S. 3094, Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act; S. 3056, CREATES Act of 2016; Proposals/Initiatives related to international intellectual property protection;

LobbyistCovered position, as disclosed
DANIEL BACHNER —
MICHAEL D BOYD —
JOHN P. FORD —
ANDREW KAPLAN —
HEATHER STRAWN —

Contacted: Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); State, Dept of (DOS); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); SENATE

Bills named: S. 2733 (114th), H.R. 5573 (114th), H.R. 971 (114th), S. 3056 (114th), S. 1767 (114th), S. 1878 (114th), S. 1421 (114th), H.R. 9 (114th), S. 632 (114th), S. 3094 (114th), H.R. 406 (114th)

Health Issues HCR

H.R. 6, 21st Century Cures Act; S. 2700, FDA and NIH Workforce Authorities Modernization Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation/Reauthorization of The Prescription Drug User Fee Act (PDUFA); Implementation/Reauthorization of The Biosimilars User Fee Act (BsUFA); H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016; H.R. 3012 & S. 2912, Trickett Wendler Right to Try Act of 2016; H.R. 6043 & S. 3335, Fair Accountability and Innovative Research Drug Pricing Act of 2016; H.R. 6174, Closing Loopholes for Orphan Drugs Act; S.3239, RACE for Children Act; Expanded Access (legislation not introduced); H.R. 4207, Medicare Fair Drug Pricing Act of 2015; Clinton's 1993 Health Security Act;

LobbyistCovered position, as disclosed
MICHAEL D BOYD —
JOHN P. FORD —
ANDREW KAPLAN —
STEPHEN SCANGO —
HEATHER STRAWN —

Contacted: Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR); Medicare Payment Advisory Commission (MedPAC); State, Dept of (DOS); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO)

Bills named: H.R. 2228 (114th), S. 3239 (114th), S. 1287 (114th), S. 481 (114th), H.R. 3012 (114th), S. 3335 (114th), H.R. 3677 (114th), S. 122 (114th), H.R. 6 (114th), H.R. 2570 (114th), S. 2912 (114th), S. 1396 (114th), H.R. 639 (114th), H.R. 6043 (114th), H.R. 4207 (114th), S. 524 (114th), S. 2700 (114th), H.R. 6174 (114th), H.R. 1101 (114th)

Budget/Appropriations BUD

H.R. 4974 & S. 2806, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2017; P.L. 114-113, Consolidated Appropriations Act, 2016 (H.R. 2029); H.R. 5325, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act; Other Labor, Health and Human Services Appropriations (no bills introduced); S. 1413, FDA User Fee Protection Act; FDAs Changes Being Effected Rule;

LobbyistCovered position, as disclosed
DANIEL BACHNER —
MICHAEL D BOYD —
JOHN P. FORD —
HEATHER STRAWN —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Medicare Payment Advisory Commission (MedPAC); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 4974 (114th), S. 2806 (114th), H.R. 2029 (114th), H.R. 5325 (114th), S. 1413 (114th)

Taxation/Internal Revenue Code TAX

Administrations Tax Reform and 2015 Budget Proposals; Senate and House Committee Tax Reform Proposals; H.R. 5278, PROMESA; Puerto Rican Economy and Debt Relief Proposals (no bills introduced); Proposals to reform domestic and international tax structures (no bills introduced);

LobbyistCovered position, as disclosed
DANIEL BACHNER —
MICHAEL D BOYD —
JOHN P. FORD —
ANDREW KAPLAN —
STEPHEN SCANGO —
HEATHER STRAWN —

Contacted: Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); SENATE; Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR)

Bills named: H.R. 5278 (114th)

Medicare/Medicaid MMM

Policies to enhance patient access to medicines in Medicaid; Policies to enhance patient access to medicines in Medicare; H.R. 2298, Medicare Patient Safety and Drug Abuse Prevention Act; H.R. 2914, Promoting Integrity in Medicare Act; H.R. 1190 & S. 141, Protecting Seniors' Access to Medicare Act of 2015 H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act; H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015; H.R. 1102 & S. 117, Medicare Prescription Drug Price Negotiation Act; H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; Medicare payment proposals (MedPAC); Medicare Access and CHIP Reauthorization Act (MACRA);

LobbyistCovered position, as disclosed
DANIEL BACHNER —
MICHAEL D BOYD —
JOHN P. FORD —
ANDREW KAPLAN —
STEPHEN SCANGO —
HEATHER STRAWN —

Contacted: Patent & Trademark Office (PTO); SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; State, Dept of (DOS)

Bills named: H.R. 3061 (114th), S. 141 (114th), S. 117 (114th), H.R. 1102 (114th), H.R. 2914 (114th), H.R. 2298 (114th), H.R. 2925 (114th), H.R. 1190 (114th), S. 31 (114th), H.R. 5122 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.